Neuropeptides for Alzheimer's Disease Research

Alzheimer’s Disease

As the sixth leading cause of death in the United States, Alzheimer’s disease, a chronic neurodegenerative disease, affects more than 5 million people in the United States alone. It is estimated that Alzheimer’s disease and other dementias will cost $236 million in medical care in 2016. Alzheimer’s disease is a progressive brain disorder that causes problems with memory, thinking, and behavior. Extracellular amyloid plaques, caused by the Amyloid β-Protein, and intracellular neurofibrillary tangles are hallmark features of the disease.1

The buildup of plaques in the brain from Amyloid β-Protein cause inflammation and neurodegeneration. Recently, P. Bhattarai and his team in Dresden, Germany, have discovered that, in zebrafish, Interleukin-4 (IL-4) is activated by neurons in response to Amyloid β-Protein, resulting in increased neuron proliferation. This discovery can lead to further research in treating human neural degradation due to Alzheimer’s.2 If scientists can figure out how to activate IL-4 in humans, the lost neurons can possibly be replaced.

In families where early-onset Alzheimer’s disease is prevalent, it is thought that a mutation in the PSEN1 gene creates a defective presenilin-1 protein. This in turn causes a disruption in the function of the γ-secretase complex.3 DAPT is an inhibitor of presenilin-dependent γ-secretase which has been shown to block Amyloid β-Protein production in neuronal cultures.4


 DAPT (IGS-3641-PI)



  2. P. Bhattarai, et al., Cell Reports, 17, 941 (2016). Retrieved from
  4. A.Y. Kornilova, et al, J. Biol. Chem., 278, 16470 (2003). Retrieved from

You can also view our products for Alzheimer's research in the online catalog here.

Authors from Peptides International

Related Articles